Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.63 |
| ▸ | TSHR | P16473 | 3/20 | 0.63 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 2/20 | 0.63 |
| ▸ | USP2 | O75604 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.56 |
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | CRHBP | P24387 | 1/20 | 0.54 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4417079 | 0.91 | TSHR (0.76) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4425115 | 0.89 | LMNA (0.64) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4428576 | 0.88 | LMNA (0.71) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4416942 | 0.88 | MAPK1 (0.74) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4418537 | 0.87 | DRD2 (0.62) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL16720328 | 0.86 | TSHR (0.72) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4419169 | 0.85 | TSHR (0.63) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4417416 | 0.85 | LMNA (0.59) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4429432 | 0.84 | LMNA (0.60) | LMNATSHRMAPK1MAPTUSP2 | |
| SCHEMBL4417103 | 0.84 | MAPT (0.61) | LMNATSHRMAPK1MAPTUSP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | LMNA 4354/4885TSHR 194/4885MAPK1 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.